Immunovant Reports Financial Results for the Quarter Ended September 30, 2021
Company Ended the Quarter With Cash of Approximately $559 MillionNEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq:...
News
Repligen Releases Inaugural Sustainability Report
Sets Baseline and Provides SASB, GRI Core and SDG DisclosuresWALTHAM, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:...
KemPharm Announces AZSTARYS® Clinical Data to be Featured in Poster Presentation at the 2021 Virtual International Conference on ADHD
Data demonstrate efficacy of AZSTARYS in children, including 30-minute onset of action and 13-hour duration of effect Corium Continues Commercialization...
MannKind Presents Data at 21st Annual Diabetes Technology Meeting
A Technosphere® Insulin (TI) dose – approximately double the estimated mealtime subcutaneously (SC) injection dose – reduced postprandial glucose excursions...
Nabriva Therapeutics to Present at the Jefferies London Healthcare Conference
DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company...
EyePoint Pharmaceuticals to Host Conference Call Highlighting Interim Phase 1 Clinical Data from Ongoing DAVIO Trial of EYP-1901 for Wet AMD
WATERTOWN, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and...
Calithera Biosciences Promotes Emil T. Kuriakose, MD, to Chief Medical Officer
-- Dr. Kuriakose to succeed Keith Orford, MD, PhD, who will assume seat on Calithera Board of DirectorsSOUTH SAN FRANCISCO,...
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on November 12, 2021
DUBLIN, Ireland and CHICAGO, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical...
Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial
--KEAPSAKE interim analysis demonstrated lack of clinical benefit among patients treated with telaglenastat --Company will focus on advancing newly acquired...
BioCryst Presents New Data Showing Sustained Reduction of HAE Attack Rates and Improved Patient Satisfaction After Patients Switch to ORLADEYO® (berotralstat)
Data from APeX-S showed patients had more than 80 percent attack free months after switching to ORLADEYO from injectable prophylactic...
Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder
Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder 5 November 2021 LONDON, Silence Therapeutics plc, AIM: SLN and...
Ocugen, Inc. Announces Submission of Emergency Use Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXIN™ (BBV152) for Children Ages 2-18 Years
COVAXIN™ (BBV152) was recently awarded Emergency Use Listing by the World Health OrganizationPediatric EUA submission based on immuno-bridging clinical trial...
Release date of nine-month interim report (Q3) 2021 for ALK and audio cast
On Thursday, 11 November 2021, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) releases its nine-month interim report...
Evaxion Biotech Announces Pricing of $24.0 Million Follow-on Public Offering
COPENHAGEN, Denmark, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...
Virbac : Declaration of the number of shares and voting rights October 2021
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information...
Smart Immune Announces Acceptance of Two Abstracts Covering Preclinical Research and Clinical Data at the American Society of Hematology
Data Presented at ASH Underscores the Potential of the Smart-Immune Platform That Can Generate ex-vivo T- cell progenitors and NK-...
Gene linked to doubling the risk of death due to COVID-19 identified using technology exclusively licensed to Nucleome Therapeutics
Gene linked to doubling the risk of death due to COVID-19 identified using technology exclusively licensed to Nucleome Therapeutics Study...
Notice of Extra General Meeting in Acarix AB
Notice of Extra General Meeting in Acarix AB The shareholders of Acarix AB, reg. no. 559009-0667, (the "Company"), are hereby...
Boosh Creates 5th Revenue Stream; Selling To The Food Service Industry
Vancouver, British Columbia--(Newsfile Corp. - November 5, 2021) - Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77I) ("Boosh" or the...
Izotropic Appoints Breast CT Expert as Head of Imaging Technology
Vancouver, British Columbia--(Newsfile Corp. - November 5, 2021) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a Company commercializing...